Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX   US5288721047

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/16/2015 01/20/2015 01/21/2015 01/22/2015 01/23/2015 Date
0.9437(c) 0.9493(c) 0.9124(c) 0.9237(c) 0.9164(c) Last
1 176 335 4 401 199 975 164 902 806 573 523 Volume
+1.72% +0.59% -3.89% +1.24% -0.79% Change
More quotes
Company
Lexicon Pharmaceuticals, Inc. engages in discovery and development of breakthrough treatments for human disease.The company primarily focuses on the discovery of the functions and pharmaceutical utility of genes and the use of those gene function discoveries in the discovery and development of... 
Sector
Biotechnology & Medical Research
Calendar
02/10 | 08:00amPresentation
More about the company
Surperformance© ratings of Lexicon Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Chart LEXICON PHARMACEUTICALS, I
Duration : Period :
Lexicon Pharmaceuticals, I Technical Analysis Chart | LXRX | US5288721047 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 13,5 M
EBIT 2014 -103 M
Net income 2014 -107 M
Debt 2014 -
Yield 2014 -
Sales 2015 13,6 M
EBIT 2015 -107 M
Net income 2015 -122 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 49,3x
Capi. / Sales 2015 48,9x
Capitalization 664 M
More Financials
Latest news on LEXICON PHARMACEUTICALS, I
01/14 LEXICON PHARMACEUTICALS : To Present At The 33rd Annual J.P. Morgan Healthcare C..
01/07 LEXICON PHARMACEUTICALS : To Present At The 33rd Annual J.P. Morgan Healthcare C..
2014 LEXICON PHARMACEUTICALS : Entry into a Material Definitive Agreement, Creation o..
2014 LEXICON PHARMACEUTICALS : To Present At The Oppenheimer 25th Annual Healthcare C..
2014 LEXICON PHARMACEUTICALS : To Present At The Oppenheimer 25th Annual Healthcare C..
2014 LEXICON PHARMACEUTICALS : Announces Proposed Common Stock Offering
2014 LEXICON PHARMACEUTICALS : Announces Pricing Of Convertible Senior Notes Offering
2014 LEXICON PHARMACEUTICALS : DE : Entry into a Material Definitive Agreement, Creat..
More news
Sector news Bio Therapeutic Drugs
01/23 INCYTE : Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Ap..
01/23 MEDIVATION : Astellas -enzalutamide phase 2 terrain trial demonstrated statistic..
01/22 QUINTILES TRANSNATIONAL : Investigator Initiated Trials is Topic of New Handbook..
Plus d'actualités du secteur Bio Therapeutic Drugs


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF